Overview: Beta-2-Glycoprotein 1 IgM TestIntroduction: The Beta-2-Glycoprotein 1 IgM Test detects IgM antibodies linked to antiphospholipid syndrome, causing blood clots or pregnancy complications. Aligned with 2023 ACR guidelines, it uses an immunoassay for high specificity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected antiphospholipid syndrome.
Other Names: Beta-2-Glycoprotein IgM Assay, APS Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Antiphospholipid antibody testing began in the 1980s with lupus anticoagulant. Beta-2-glycoprotein assays emerged in the 1990s, and by the 2000s, immunoassays improved specificity for APS.
Purpose: Diagnoses antiphospholipid syndrome, guides treatment, and monitors antibody levels in patients with blood clots or pregnancy complications.
Test Parameters: 1. Beta 2 Glycoprotein 1 IgM
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like blood clots or miscarriages, and list medications like anticoagulants.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document clotting events, pregnancy complications, or family history of APS. Include current medications, especially anticoagulants or aspirin.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for anticoagulant therapy.
Procedural Considerations: Uses an immunoassay to measure beta-2-glycoprotein IgM antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Immunosuppressants may suppress antibody levels, causing false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm APS, prompting anticoagulant therapy. Negative results may require IgA or IgG testing for confirmation.
Specialist Consultation: Consult a rheumatologist for result interpretation. A hematologist or obstetrician referral is advised for clotting or pregnancy cases.
Additional Supporting Tests: Lupus anticoagulant test, anticardiolipin antibodies, or Doppler ultrasound to confirm APS or assess clotting risk.
Test Limitations: False negatives may occur with early disease or immunosuppression. Results require clinical correlation.
References: ACR APS Guidelines, 2023; Arthritis and Rheumatology, Miyakis S, 2022.
